<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Sci Rep</journal-id>
    <journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id>
    <journal-title-group>
      <journal-title>Scientific Reports</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2045-2322</issn>
    <publisher>
      <publisher-name>Nature Publishing Group UK</publisher-name>
      <publisher-loc>London</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">5709354</article-id>
    <article-id pub-id-type="publisher-id">16747</article-id>
    <article-id pub-id-type="doi">10.1038/s41598-017-16747-x</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Eide</surname>
          <given-names>Peter W.</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff2">2</xref>
        <xref ref-type="aff" rid="Aff3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Bruun</surname>
          <given-names>Jarle</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Lothe</surname>
          <given-names>Ragnhild A.</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff2">2</xref>
        <xref ref-type="aff" rid="Aff3">3</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8219-6251</contrib-id>
        <name>
          <surname>Sveen</surname>
          <given-names>Anita</given-names>
        </name>
        <address>
          <email>anita.sveen@rr-research.no</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0389 8485</institution-id><institution-id institution-id-type="GRID">grid.55325.34</institution-id><institution>Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, </institution></institution-wrap>Oslo, NO-0424 Norway </aff>
      <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0389 8485</institution-id><institution-id institution-id-type="GRID">grid.55325.34</institution-id><institution>K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, </institution></institution-wrap>Oslo, NO-0424 Norway </aff>
      <aff id="Aff3"><label>3</label>Institute for Clinical Medicine, University of Oslo, Oslo, NO-0318 Norway </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>30</day>
      <month>11</month>
      <year>2017</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>30</day>
      <month>11</month>
      <year>2017</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2017</year>
    </pub-date>
    <volume>7</volume>
    <elocation-id>16618</elocation-id>
    <history>
      <date date-type="received">
        <day>7</day>
        <month>6</month>
        <year>2017</year>
      </date>
      <date date-type="accepted">
        <day>15</day>
        <month>11</month>
        <year>2017</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2017</copyright-statement>
      <license license-type="OpenAccess">
        <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
      </license>
    </permissions>
    <abstract id="Abs1">
      <p id="Par1">Colorectal cancers (CRCs) can be divided into four gene expression-based biologically distinct consensus molecular subtypes (CMS). This classification provides a potential framework for stratified treatment, but to identify novel CMS-drug associations, translation of the subtypes to pre-clinical models is essential. The currently available classifier is dependent on gene expression signals from the immune and stromal compartments of tumors and fails to identify the poor-prognostic CM<xref rid="MOESM2" ref-type="media">S4</xref>-mesenchymal group in immortalized cell lines, patient-derived organoids and xenografts. To address this, we present a novel CMS classifier based on a filtered set of cancer cell-intrinsic, subtype-enriched gene expression markers. This new classifier, referred to as CMScaller, recapitulated the subtypes in both <italic>in vitro</italic> and <italic>in vivo</italic> models (551 in total). Importantly, by analyzing public drug response data from patient-derived xenografts and cell lines, we show that the subtypes are predictive of response to standard CRC drugs. CMScaller is available as an R package.</p>
    </abstract>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>© The Author(s) 2017</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1" sec-type="introduction">
    <title>Introduction</title>
    <p id="Par2">Colorectal cancer (CRC) is the fourth most common cause of cancer deaths worldwide<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Gene expression profiling shows promise to identify clinically important subtypes<sup><xref ref-type="bibr" rid="CR2">2</xref>–<xref ref-type="bibr" rid="CR6">6</xref></sup>, including a mesenchymal-like subgroup with high stromal infiltration, poor patient prognosis<sup><xref ref-type="bibr" rid="CR7">7</xref></sup> and poor response to standard treatments such as oxaliplatin<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> and antibodies against EGFR<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR9">9</xref></sup>. Based on gene expression profiles from close to 4000 primary tumors, an expert consortium recently proposed a classification scheme reconciling this work and dividing CRCs into four biologically distinct subtypes<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. In this consensus system, CM<xref rid="MOESM2" ref-type="media">S1</xref>-immune comprises most tumors with microsatellite instability (MSI) and is characterized by infiltration of activated immune cells. CM<xref rid="MOESM2" ref-type="media">S2</xref>-canonical and CM<xref rid="MOESM2" ref-type="media">S3</xref>-metabolic both show epithelial characteristics, with oncogene amplification and high WNT and MYC signaling predominantly in CM<xref rid="MOESM2" ref-type="media">S2</xref> and metabolic reprogramming in CM<xref rid="MOESM2" ref-type="media">S3</xref>. CM<xref rid="MOESM2" ref-type="media">S4</xref> comprises the more mesenchymal-like cancers, with high stromal infiltration and poor patient prognosis<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>. So far, identification of subtype-specific drug responses has only scratched the surface, and CMS classification presents an unexploited basis for stratified treatment and drug repurposing in CRC.</p>
    <p id="Par3"><italic>In vitro</italic> and <italic>in vivo</italic> models of CRC recapitulate the molecular profiles of primary cancers<sup><xref ref-type="bibr" rid="CR12">12</xref>–<xref ref-type="bibr" rid="CR15">15</xref></sup>, as well as clinically relevant pharmacogenomic associations and are suitable tools for drug discovery<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR17">17</xref></sup>. Publicly available data from pre-clinical drug screen studies represent an invaluable resource, however, analysis of CMS-drug associations is hindered by imprecise subtyping of the models. The original classifier was developed specifically for primary CRCs (pCRC), and it was recently shown that it fails to identify the CM<xref rid="MOESM2" ref-type="media">S1</xref>-immune and CM<xref rid="MOESM2" ref-type="media">S4</xref>-mesenchymal groups in cell lines, patient-derived organoids and xenografts (PDX)<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR18">18</xref>–<xref ref-type="bibr" rid="CR20">20</xref></sup>, due to the absence of human immune-related signatures, stromal components and extra-cellular matrix in cell cultures and animal models<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR18">18</xref>–<xref ref-type="bibr" rid="CR22">22</xref></sup>. However, at least some CRC cell lines are mesenchymal-like<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR24">24</xref></sup> and both organoids and PDXs can be established with minimal bias in terms of clinical and molecular covariates of the originating tumors<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR25">25</xref></sup>. This indicates that the apparent lack of CM<xref rid="MOESM2" ref-type="media">S4</xref>-like models is not a result of biological adaptation to or selection for culturing conditions. We aimed to develop a classifier optimized for pre-clinical models and introduce here CMScaller, an algorithm for CMS classification in the absence of human tumor stroma. We apply CMScaller to <italic>in vitro</italic> and <italic>in vivo</italic> models with publicly available gene expression data and show that it enables pre-clinical analysis of CMS-drug associations.</p>
  </sec>
  <sec id="Sec2" sec-type="results">
    <title>Results</title>
    <sec id="Sec3">
      <title>Pre-clinical models require a cancer cell-intrinsic CMS classifier</title>
      <p id="Par4">To illustrate why the original CMS classifier is not applicable to pre-clinical models, the classifyCMS.RF function in the R package CMSclassifier<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR26">26</xref></sup> was applied to gene expression data from CRC cell lines (<italic>n</italic> = 131)<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>, organoids (<italic>n</italic> = 22 + 26)<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup> and PDXs (<italic>n</italic> = 40 + 37 + 51 + 244)<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR29">29</xref></sup>. Of all 551 samples, 219 (66%) were unclassified using default parameters. Among the classified, 245 (74%) were CM<xref rid="MOESM2" ref-type="media">S2</xref>, and only 3 samples (0.9%) were identified as CM<xref rid="MOESM2" ref-type="media">S4</xref>-mesenchymal (Supplementary Table <xref rid="MOESM1" ref-type="media">1</xref>). In one PDX dataset predicted to lack the CM<xref rid="MOESM2" ref-type="media">S4</xref> subtype, single-sample gene set expression enrichment analysis indicated strong TGFβ response and MSS-like characteristics in two samples, reminiscent of CM<xref rid="MOESM2" ref-type="media">S4</xref> characteristics (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>).<fig id="Fig1"><label>Figure 1</label><caption><p>CM<xref rid="MOESM2" ref-type="media">S4</xref>-mesenchymal markers in primary cancer are partially lost upon xenografting. (<bold>a</bold>) Single-sample gene expression enrichment scores for gene sets of TGFβ responses versus MSS-like characteristics identify two PDX models with particularly strong CM<xref rid="MOESM2" ref-type="media">S4</xref> characteristics (encircled). Samples are colored according to CMS predictions based on the original CMSclassifier. (<bold>b</bold>) Differential gene expression between pCRCs and PDX models, plotted against mean overall expression, indicates that genes included as markers in the original CMSclassifier and highly expressed in CM<xref rid="MOESM2" ref-type="media">S4</xref> primary tumors (green) show reduced expression in PDXs. The top-5 differentially expressed genes are labeled. Units are log<sub>2</sub>(signal). (<bold>c</bold>) Volcano plot of differential expression analysis of CM<xref rid="MOESM2" ref-type="media">S4</xref> versus CM<xref rid="MOESM2" ref-type="media">S1</xref>/<xref rid="MOESM2" ref-type="media">2</xref>/<xref rid="MOESM2" ref-type="media">3</xref> primary CRCs. Highlighted in purple are the genes differentially expressed between pCRCs and PDXs (absolute LFC &gt; 2). The five genes with the largest absolute difference between CM<xref rid="MOESM2" ref-type="media">S4</xref> and CM<xref rid="MOESM2" ref-type="media">S1</xref>/<xref rid="MOESM2" ref-type="media">2</xref>/<xref rid="MOESM2" ref-type="media">3</xref> are labeled. CMS: consensus molecular subtype; LFC: log<sub>2</sub>fold-change; MSI/MSS: micro-satellite instable/stable; PDX: patient-derived xenograft; pCRC: primary colorectal cancer.</p></caption><graphic xlink:href="41598_2017_16747_Fig1_HTML" id="d29e504"/></fig>
</p>
      <p id="Par5">To identify genes expressed in or induced by the human tumor microenvironment and therefore with reduced levels in xenotransplants, we performed differential gene expression analysis comparing 30 pCRCs against 40 PDX models<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. A significant proportion of genes (44/178, 25%) included as features in the original CMS classifier and highly expressed in CM<xref rid="MOESM2" ref-type="media">S4</xref> pCRC were reduced or almost completely lost in the PDX samples (<italic>log</italic>
<sub>2</sub>fold-change (LFC) &gt; 2, Fig. <xref rid="Fig1" ref-type="fig">1b</xref>). Considering all 108 candidate CM<xref rid="MOESM2" ref-type="media">S4</xref> genes with reduced expression in the PDXs, the set was significantly enriched for genes involved in biological pathways characteristic of the tumor stroma, including epithelial to mesenchymal transition (EMT), extracellular matrix organization and angiogenesis, which ranked 1<sup>st</sup>, 2<sup>nd</sup> and 8<sup>th</sup> in terms of significance among 2038 unselected gene sets from reactome.org<sup><xref ref-type="bibr" rid="CR30">30</xref></sup> and MSigDB Hallmarks<sup><xref ref-type="bibr" rid="CR31">31</xref></sup> (hypergeometric test, Supplementary Table <xref rid="MOESM1" ref-type="media">2</xref>). Of the 11921 genes overlapping between the pCRC and PDX datasets, 11753 genes showed low differential expression between pCRCs and PDXs (pCRC-PDX LFC &lt; 2, no <italic>p</italic>-value threshold), 921 (7.8%) of these were identified as differentially expressed between CM<xref rid="MOESM2" ref-type="media">S4</xref> and CM<xref rid="MOESM2" ref-type="media">S1</xref>/2/3 in pCRCs (LFC &gt; 1, false discovery rate adjusted-<italic>p</italic> &lt; 0.1), indicating that CM<xref rid="MOESM2" ref-type="media">S4</xref> cancer cells present intrinsic gene expression signals that can be used for subtyping (Fig. <xref rid="Fig1" ref-type="fig">1c</xref>).</p>
    </sec>
    <sec id="Sec4">
      <title>Development, application and evaluation of the cancer cell-adapted CMScaller</title>
      <p id="Par6">Accordingly, to construct a classifier useful for pre-clinical models, we set out to identify cancer cell-intrinsic subtype markers by selecting genes that (i) were highly expressed in each CMS group compared with the rest in pCRCs (LFC &gt; 1, adjusted-<italic>p</italic> &lt; 0.1; representing candidate markers), (ii) had a large range in expression values across a panel of CRC cell lines<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> (top-25% 10–90 cross-sample inter-percentile range) and were highly expressed in at least a subset (top-25% within-sample read count in at least three cell lines; representing markers that are informative in cancer cells) and (iii) were not lost upon xenotransplantation<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> (pCRC-PDX LFC &lt; 2, no <italic>p</italic>-value threshold; representing cancer cell-intrinsic markers, Fig. <xref rid="Fig2" ref-type="fig">2a</xref>).<fig id="Fig2"><label>Figure 2</label><caption><p>CMScaller feature selection and performance in pCRC. (<bold>a</bold>) Schematic illustration of gene filtering-approach. Three different datasets (top) were used to identify robust cancer cell-enriched subtype markers (only genes represented in all three datasets were considered). (<bold>b</bold>) CMScaller performance on the test set of pCRCs from TCGA (n = 143). Heatmap shows the relative expression levels of subtype marker genes (vertical bar) with classifications indicated below (horizontal bar, white indicate prediction confidence p-values). (<bold>c</bold>) Plot shows results from principal component analysis (expression data batch-adjusted for sequencing-platform). Disagreements between CMScaller and CMSclassifier are indicated with diamonds. (<bold>d</bold>) Heatmap shows results from mRNA gene set analysis, confirming enrichment of known characteristics in each CMS group (details of the gene sets are given in Supplementary Table <xref rid="MOESM1" ref-type="media">3</xref>). Red and blue indicate relative up- and down-regulation, respectively, and color saturation represents increasing statistical significance, as indicated. dn: down-regulation; n/p: number of samples/features; NA: not assigned; PC: principal component; PDX: patient-derived xenograft; pCRC: primary colorectal cancer; RNA-seq: RNA-sequencing; TCGA: The Cancer Genome Atlas; up: up-regulation.</p></caption><graphic xlink:href="41598_2017_16747_Fig2_HTML" id="d29e614"/></fig>
</p>
      <p id="Par7">The filtered gene set was used as input for nearest template prediction<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>, resulting in the CMScaller algorithm (Fig. <xref rid="Fig2" ref-type="fig">2b</xref>). Although created for pre-clinical models, CMScaller performed well also in pCRCs. Using the original CMS classifications as reference for pCRCs from TCGA, the overall prediction accuracy was 0.83 (95% confidence interval 0.74–0.9, <italic>p</italic> = 1.5 × 10<sup>−13</sup>, binomial test for accuracy better than no information rate). Lowest class-wise sensitivity and specificity were found for CM<xref rid="MOESM2" ref-type="media">S3</xref> (0.71) and CM<xref rid="MOESM2" ref-type="media">S4</xref> (0.91), respectively (Supplementary Table <xref rid="MOESM1" ref-type="media">4</xref>). However, gene expression-based principal component analysis showed that most disagreements were at class-boundaries, where the CMS groups are least distinct (Fig. <xref rid="Fig2" ref-type="fig">2c</xref>).</p>
      <p id="Par8">Cell lines represent 100% cancer, and the rationale for adding the CRC cell line-filter was to exclude markers of non-carcinoma cell types (genes preferentially expressed by the tumor stroma will not have high expression or expression variation in CRC cell lines). Furthermore, genes with large variation in expression between cell lines are likely to be informative on intrinsic phenotype. To reduce the problem of calling expressed <italic>versus</italic> non-expressed genes, a dataset based on RNA-sequencing (rather than microarray data) was applied. However, to test how sensitive CMScaller is to thresholds and data sets used during development, we generated four additional prediction template gene sets with the following changes: (i) adjusted-<italic>p</italic> threshold for differential expression analysis reduced from 0.1 to 10<sup>–4</sup> in comparisons among subtypes in pCRC; (ii) selected CRC cell line panel<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> replaced with another independent RNA sequencing-based dataset<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>; (iii) pCRC-PDX LFC threshold reduced from two to one and (iv) any gene independently reported as lost in PDXs by Isella <italic>et al</italic>. was excluded<sup><xref ref-type="bibr" rid="CR7">7</xref></sup> (Supplementary Fig. <xref rid="MOESM1" ref-type="media">1a,b</xref>). For the four resulting classifiers, the number of genes overlapping with the original CMScaller template set ranged from 205 to 459 (21–95% overlap in features). These 1 + 4 templates were used to perform five independent classifications on the Gao <italic>et al</italic>. PDX models<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> (Supplementary Fig. <xref rid="MOESM1" ref-type="media">1b,c</xref>). The classification concordance ranged from 0.95 to 0.98 and, critically, 47/50 samples (94%) were consistently assigned to a single CMS using all templates (the last sample was consistently unclassified).</p>
      <p id="Par9">We have previously provided CMS classification of widely used, immortalized CRC cell lines, and shown that these <italic>in vitro</italic> models recapitulate the properties of the CMS groups [Sveen submitted]. Here, we demonstrate that CMScaller can robustly classify also CRC organoids and PDXs, and outperforms the original CMSclassifier in seven publicly available datasets, including 26<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> and 22 organoids<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>, 40<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>, 37<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>, 51<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> and 244<sup><xref ref-type="bibr" rid="CR20">20</xref></sup> PDX models, as well as a dataset of 131<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> cell lines. Using the original CMSclassifier, most samples were classified as CM<xref rid="MOESM2" ref-type="media">S2</xref>, and only 3/551 as CM<xref rid="MOESM2" ref-type="media">S4</xref> (Supplementary Table <xref rid="MOESM1" ref-type="media">1</xref>). In contrast, using CMScaller, all CMS groups were found to be present in all datasets and CM<xref rid="MOESM2" ref-type="media">S4</xref> accounted for 7.5–22% of the samples (Supplementary Table <xref rid="MOESM1" ref-type="media">5</xref>). Notably, 46% of the metastatic CRC-derived PDXs were not assigned any CMS, perhaps due to biased representation of individual CMS groups compared to primary CRCs (ref. Discussion).</p>
      <p id="Par10">Gene set expression analyses showed that known CMS group associations were recapitulated in both organoids and PDX models (Fig. <xref rid="Fig3" ref-type="fig">3a,b</xref>). Specifically, CM<xref rid="MOESM2" ref-type="media">S1</xref> was MSI-like, CM<xref rid="MOESM2" ref-type="media">S2</xref> was MSS-like, had activated HNF4A, MYC and WNT target gene sets, CM<xref rid="MOESM2" ref-type="media">S3</xref> had up-regulated CDX2 targets and metabolic processes, and CM<xref rid="MOESM2" ref-type="media">S4</xref> models showed strong relative activation of TGFβ and EMT. The same pattern was not seen for predictions based on the original CMSclassifier (Supplementary Fig. <xref rid="MOESM1" ref-type="media">2</xref>). To further support the validity of our subtyping, we analyzed additional molecular data available in two of the datasets, including MSI-status in organoids from Fujii <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> and mutation data in PDXs from Gao <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. In the organoids, in line with expectations, 5/6 MSI samples were predicted to be CM<xref rid="MOESM2" ref-type="media">S1</xref>-immune (CM<xref rid="MOESM2" ref-type="media">S1</xref>/MSI: <italic>p</italic> = 1.6 × 10<sup>−4</sup>, Fisher’s exact test). In the PDXs, both the number of total mutations and <italic>BRAF</italic> mutations were significantly higher in CM<xref rid="MOESM2" ref-type="media">S1</xref> models (Fig. <xref rid="Fig3" ref-type="fig">3c,d</xref>, number of mutations: <italic>p</italic> = 9.9 × 10<sup>−4</sup>, Mann-Whitney test and <italic>BRAF</italic>: <italic>p</italic> = 4× 10<sup>−4</sup>, Fisher’s exact test), and the median number of copy number aberrations was 216 for CM<xref rid="MOESM2" ref-type="media">S2</xref>, significantly higher than 112 for non-CM<xref rid="MOESM2" ref-type="media">S2</xref> (<italic>p</italic> = 5.9× 10<sup>−3</sup>, Mann-Whitney test).<fig id="Fig3"><label>Figure 3</label><caption><p>CMS classified PDXs recapitulate relative drug responses observed in patients. (<bold>a</bold>) Heatmap visualization of mRNA gene set analysis showing selected CMS-informative signatures for comparisons of organoids (n = 48) classified with CMScaller. Red and blue indicate relative up- and down-regulation, respectively, and color saturation reflects statistical significance. (<bold>b</bold>) Same as a, but for a merged dataset of PDX models (n = 128). (<bold>c</bold>) Plot showing the number of mutations against the number of copy number aberrations (number of genes affected) per sample. Samples are colored according to CMScaller predictions. Horizontal axis is log-transformed for clarity. (<bold>d</bold>) Barplot showing distribution of <italic>KRAS</italic> and <italic>BRAF</italic> mutations per subtype. (<bold>e</bold>) Response to cetuximab as measured by change in tumor volume (best average response) among PDXs stratified by CMS subtype. (<bold>f</bold>) Response to 5-fluorouracil as measured by change in tumor volume (best average response) among PDXs stratified by CMS subtype. CMS: consensus molecular subtype; mut: mutation; PDX: patient-derived xenograft; wt: wild type</p></caption><graphic xlink:href="41598_2017_16747_Fig3_HTML" id="d29e853"/></fig>
</p>
      <p id="Par11">To further evaluate the performance of CMScaller, its prediction accuracy and robustness was compared with the original CMS classifications of pCRCs from TCGA in two ways. First, accuracy was evaluated in relation to sample size by dividing the pCRCs into random subsets (<italic>n</italic> = 1000) of varying sizes (range 10–80 samples). Accuracy distributions indicated that prediction uncertainties were relatively low when sample sizes exceeded more than approximately 40 samples (Supplementary Fig. <xref rid="MOESM1" ref-type="media">3</xref>). Second, robustness was evaluated by analyzing whether the CMScaller classifications were “cycle consistent” across the sample types. In other words, we tested whether the Gao <italic>et al</italic>. PDX models (<italic>n</italic> = 51) and assigned CMS groups could be used to derive an independent classifier applicable to the pCRCs (CMS<sub>PDX</sub> ↔ CMS<sub>CRC</sub>). Using the same strategy as for development of CMScaller, we performed differential expression analysis among the CMS groups to identify subtype markers, this time in PDX models, and filtered out the genes overlapping with the CMScaller template. Overall subtyping accuracy was 0.83 (95% confidence interval 0.74–0.9, <italic>p</italic> = 6.3× 10<sup>−12</sup>, binomial test for accuracy better than no information rate, Supplementary Table <xref rid="MOESM1" ref-type="media">6</xref>), indicating that the PDX models and assigned CMS groups represent real biological characteristics of CMS (Supplementary Fig. <xref rid="MOESM1" ref-type="media">4</xref>).</p>
    </sec>
    <sec id="Sec5">
      <title>Pre-clinical models recapitulate CMS-associations to standard CRC drugs</title>
      <p id="Par12">Pre-clinical analysis of CMS-drug associations is an important application of CMScaller. To illustrate this potential, we analyzed publicly available drug response data for the standard CRC drugs 5-fluorouracil (5-FU) and cetuximab (anti-EGFR) in 51 CRC PDX models<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. The Sadanandam <italic>et al</italic>. transit-amplifying subtype, largely corresponding to CM<xref rid="MOESM2" ref-type="media">S2</xref>, has previously been shown to be particularly sensitive to EGFR-inhibitors <italic>in vitro</italic>
<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup>, and <italic>in vivo</italic> response has been shown in PDX models with high WNT signaling<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. We confirm strong <italic>in vivo</italic> response to cetuximab particularly in PDX models predicted to belong to the CM<xref rid="MOESM2" ref-type="media">S2</xref> group (<italic>p</italic> = 0.024, CM<xref rid="MOESM2" ref-type="media">S2</xref> versus non-CM<xref rid="MOESM2" ref-type="media">S2</xref>, Mann-Whitney test, Fig. <xref rid="Fig3" ref-type="fig">3e</xref>), independent of <italic>KRAS/NRAS/BRAF</italic> mutations (<italic>p</italic> = 0.016, triple wild types only, CM<xref rid="MOESM2" ref-type="media">S2</xref> versus non-CM<xref rid="MOESM2" ref-type="media">S2</xref>, Mann-Whitney test). Importantly, the same association was observed for the dataset of PDXs derived from metastatic CRCs<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>, representing a clinical setting where anti-EGFR treatment is routinely used (<italic>p</italic> = 0.01, OR = 2.9, CM<xref rid="MOESM2" ref-type="media">S2</xref> versus non-CM<xref rid="MOESM2" ref-type="media">S2</xref> independent of <italic>KRAS/BRAF/NRAS</italic> status, Fisher’s Exact test, Supplementary Fig. <xref rid="MOESM1" ref-type="media">5a</xref>). Analysis of CRC cell lines with public gene expression data<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> and cetuximab response data<sup><xref ref-type="bibr" rid="CR35">35</xref></sup> (only non-duplicated cell lines with assigned CMS, <italic>n</italic> = 40, Supplementary Fig. <xref rid="MOESM1" ref-type="media">5b</xref>) confirmed our previous finding [Sveen submitted] that CM<xref rid="MOESM2" ref-type="media">S2</xref> was significantly associated with response to cetuximab also <italic>in vitro</italic> (<italic>p</italic> = 3.4× 10<sup>−3</sup>, OR = 8.3, CM<xref rid="MOESM2" ref-type="media">S2</xref> versus non-CM<xref rid="MOESM2" ref-type="media">S2</xref>, Fisher’s Exact test).</p>
      <p id="Par13">Patients with MSI tumors have been shown to respond poorly to 5-FU<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>, and consistently, 5-FU had poor anti-tumor activity in CM<xref rid="MOESM2" ref-type="media">S1</xref>-immune PDXs (Fig. <xref rid="Fig3" ref-type="fig">3f</xref>). Furthermore, CM<xref rid="MOESM2" ref-type="media">S4</xref> also showed a poor response to 5-FU compared with CM<xref rid="MOESM2" ref-type="media">S2</xref>/3 PDXs (<italic>p</italic> = <inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$0.12$$\end{document}</tex-math><mml:math id="M2"><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mo>.</mml:mo></mml:mrow><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="41598_2017_16747_Article_IEq1.gif"/></alternatives></inline-formula>, CM<xref rid="MOESM2" ref-type="media">S4</xref> vs CM<xref rid="MOESM2" ref-type="media">S2</xref>/3 Mann-Whitney test), although the sample number was small (<italic>n</italic>
<sub>CMS4</sub> = 4). For validation, and to eliminate the potential effect of MSI, we analyzed <italic>in vitro</italic> 5-FU response data for a set of MSS CRC cell lines<sup><xref ref-type="bibr" rid="CR37">37</xref></sup> (only non-duplicated MSS cell lines with assigned CMS, <italic>n</italic> = 34, Supplementary Fig. <xref rid="MOESM1" ref-type="media">6</xref>). In CM<xref rid="MOESM2" ref-type="media">S1</xref>-CM<xref rid="MOESM2" ref-type="media">S4</xref> cell lines, the median concentrations required for 50% growth inhibition were 1.1, 1.1, 4.1 and 6.8 µM 5-FU respectively, confirming a poor response in CM<xref rid="MOESM2" ref-type="media">S4</xref> (<italic>p</italic> = 7.2 × 10<sup>−3</sup>, CM<xref rid="MOESM2" ref-type="media">S4</xref> vs CM<xref rid="MOESM2" ref-type="media">S1/2</xref>/<xref rid="MOESM2" ref-type="media">3</xref> Mann-Whitney test).</p>
    </sec>
  </sec>
  <sec id="Sec6" sec-type="discussion">
    <title>Discussion</title>
    <p id="Par14">Pre-clinical models are invaluable tools for drug discovery, but identification of pharmacogenomic associations depends on accurate molecular subtyping. We report the development and performance of CMScaller, a CMS classifier optimized for pre-clinical model systems of primary colorectal cancer, including cell lines, organoids and xenografts. We illustrate the potential of CMScaller to identify CMS-associated responses to standard CRC drugs, including 5-FU-based chemotherapy, the most widely used oncological treatment regimen in CRC. In patients, treatment is contraindicated in the MSI subtype, but response rates are incomplete also within the MSS group. The PDX and cell line drug response data presented here suggest that the CMS-groups add additional predictive information, indicating a poor response in CM<xref rid="MOESM2" ref-type="media">S4</xref>. In concordance, previous studies have shown limited benefit from chemotherapy in patients with mesenchymal tumors<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>, also when adding oxaliplatin<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>, and there is mounting evidence that stromal cells confer resistance to chemotherapy<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. However, these pre-clinical data indicate that the CM<xref rid="MOESM2" ref-type="media">S4</xref> group has cancer cell-intrinsic characteristics conferring poor response also in the absence of the tumor microenvironment.</p>
    <p id="Par15">It has been suggested that CM<xref rid="MOESM2" ref-type="media">S4</xref> and the related stem-cell/serrated/mesenchymal subtypes mainly reflect tumors dominated by infiltrating stromal cells. Accordingly, novel CRC classifications based on cancer cell-intrinsic gene expression signals were recently proposed<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR40">40</xref></sup>. There is an interplay between cancer and stromal cells and we hypothesized that the stromal composition in part is determined by cancer-cell intrinsic features. Thus, analogously to how it is reasonable to assume that CM<xref rid="MOESM2" ref-type="media">S1</xref> cancer cell-intrinsic immunogenicity may explain the infiltration of activated immune cells in the tumor microenvironment, particular aspects of CM<xref rid="MOESM2" ref-type="media">S4</xref> cancer cells may lead to aggressive growth intimately associated with the formation of tumors with abundant cancer-associated fibroblasts and a poor clinical outcome. In a related work, we showed that undifferentiated CRC cell lines, predominately CM<xref rid="MOESM2" ref-type="media">S1</xref> and CM<xref rid="MOESM2" ref-type="media">S4</xref>, had elevated mRNA expression of <italic>TGFB1</italic> and <italic>TGFB2</italic>, encoding TGFβ cytokines<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. It is therefore tempting to speculate that CM<xref rid="MOESM2" ref-type="media">S4</xref> cancer cells through such paracrine signaling are actively remodeling their microenvironments.</p>
    <p id="Par16">CMScaller was developed to provide robust classification across gene expression platforms. This is demonstrated by gene set analyses recapitulating the hallmarks of each CMS group in datasets generated on different technological platforms and for different biological sample types. Robustness can in part be ascribed to the fact that gene expression is highly co-regulated and, despite of thousands of features, informationally surprisingly low-dimensional<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. Consequently, missing, noisy or erroneous measurements are compensated for by other co-regulated genes in the nearest template prediction algorithm applied<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. This may also explain why the tested changes to the template gene set had little impact on the resulting sample classifications.</p>
    <p id="Par17">Although the template genes were selected to enrich for cancer-cell intrinsic signals, they are not exclusively expressed by cancer cells. For example, the CM<xref rid="MOESM2" ref-type="media">S4</xref> marker <italic>VIM</italic> is expressed in fibroblasts, but have higher expression among CM<xref rid="MOESM2" ref-type="media">S4</xref> cancer cells than CM2–3 and is therefore a useful template gene. Importantly, stricter gene filtering for stromal expression had limited impact on the resulting classifications. Still, CMScaller in its current implementation is not recommended for use with samples with a different human stromal component than primary CRCs, including <italic>e</italic>.<italic>g</italic>. patient biopsies of metastatic CRC. Another inherent limitation to CMScaller is that the input gene expression data should be centered and scaled. The implication is that small datasets inescapably introduce prediction uncertainty, due to the potential for biased representation of either subtype. Our estimations indicate that this is a concern for datasets with fewer than approximately forty samples, but becomes minor when <italic>n</italic> exceeds this limit. Similarly, caution is warranted in highly selected datasets where molecular distributions are expected, or known, to severely deviate from pCRC cohorts, including metastatic samples<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. Importantly, for both organoids and PDXs, it has been shown that the models recapitulate the heterogeneity of their original tumors<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR25">25</xref></sup>. However, to assess potential bias, we recommend analyzing CMS-associations of additional molecular markers, for instance MSI-status and <italic>BRAF</italic> mutations. Additionally, CMScaller includes a function for downstream gene set expression analyses, allowing for assessment of CMS hallmarks.</p>
    <p id="Par18">Within its proper context of pCRC-derived cohorts, accuracy assessment of CMScaller indicated that prediction errors were mainly made at the class boundaries, where expression patterns are less distinct. This may be explained by intra-tumor heterogeneity<sup><xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR44">44</xref></sup>, both from immune/stromal infiltration (tumor cell percentage and stromal composition) and intrinsic to the cancer cells<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. The extent of heterogeneity of molecular subtyping has recently been illustrated by single cell RNA-sequencing<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. We have tested CMScaller on these data, and fair correspondence in CMS group assignments was obtained for individual cancer cells from the same patient. However, with only ten patients, the number was too low to draw any strong conclusions whether CMScaller is useful with such data inputs. From a technical perspective, single-cell RNA-sequencing data is exceedingly noisy and a classifier should be optimized for and take advantage of the digital nature of such data. We envision implementing this as a future option in the CMScaller package, as well as to further improve the prediction template gene set taking advantage of larger, higher-quality datasets as they become available.</p>
    <p id="Par19">In addition to pre-clinical drug response studies, model systems may also be useful for functional analyses of central CMS-associated characteristics in controlled environments. The CMScaller presented here should enable the matching of patient subtypes with appropriate models, and we hope this will be a useful tool for the research community. CMScaller is platform independent and available as an R package.</p>
  </sec>
  <sec id="Sec7" sec-type="materials|methods">
    <title>Methods</title>
    <sec id="Sec8">
      <title>Gene expression and drug response data</title>
      <p id="Par20">Klijn <italic>et al</italic>. colorectal, liver and stomach cancer cell line mRNA and non-coding RNA-sequencing counts were downloaded from ref.<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>, non-Entrez features were discarded and pre-processing was performed by conditional quantile normalization and variance stabilization using cqn<sup><xref ref-type="bibr" rid="CR47">47</xref></sup> and DESeq2<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>. Gao <italic>et al</italic>. PDX RNA-sequencing FPKM values were retrieved from Supplementary Table <xref rid="MOESM1" ref-type="media">1</xref> in ref.<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. GSE35144<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>, GSE64392<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>, GSE74843<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> and E-MTAB-991<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> PDX/organoid microarray gene expression datasets were downloaded from GEO<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>/ArrayExpress<sup><xref ref-type="bibr" rid="CR50">50</xref></sup> and CEL files were pre-processed using the justRMA function in the R package affy<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>, with brainarray Entrez v20 CDFs<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>. Preprocessed cell line and PDX Illumina BeadArray data were downloaded from GSE59857<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> and GSE76402<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>, <italic>log</italic>
<sub>2</sub>transformed and quantile normalized. TCGA level 3 RSEM gene-level RNA-sequencing data<sup><xref ref-type="bibr" rid="CR53">53</xref></sup> was downloaded from Broad GDAC Firehose [doi:10.7908/C11G0KM9]. For all datasets, non-CRC, neuro-endocrine cancers and same-patient duplicates were discarded prior to analysis. Gao <italic>et al</italic>. PDX drug response data is from ref.<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> Supplementary Table <xref rid="MOESM1" ref-type="media">1</xref>. Isella <italic>et al</italic>. PDX cetuximab response data is from GSE76402. Cell line MSI-status and 5-FU response data were retrieved from Supplementary Tables <xref rid="MOESM1" ref-type="media">1</xref>,<xref rid="MOESM1" ref-type="media">2</xref> in ref.<sup><xref ref-type="bibr" rid="CR37">37</xref></sup> and cetuximab response groups from Fig. <xref rid="Fig2" ref-type="fig">2</xref> in ref.<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>.</p>
    </sec>
    <sec id="Sec9">
      <title>Gene expression analysis</title>
      <p id="Par21">Single sample gene set enrichment analysis was performed with the R package GSVA<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>. Differential gene expression analysis was performed using limma<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. For RNA-sequencing data, voom transformation with quantile normalization was performed prior to the limma modeling<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>. Principal component analysis was performed using the 1000 genes with the largest 10–90% inter-percentile range in expression values as input. RNA-sequencing data was first <italic>log</italic>
<sub><italic>2-</italic></sub>transformed and batch adjusted according to sequencing platform (HiSeq/GAIIx) using the ComBat method implemented in the R package sva<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>.</p>
    </sec>
    <sec id="Sec10">
      <title>Gene set tests</title>
      <p id="Par22">For CMS marker genes down-regulated in the pCRC <italic>versus</italic> PDX comparison, statistical enrichment among 2038 unselected gene sets retrieved from reactome.org<sup><xref ref-type="bibr" rid="CR30">30</xref></sup> and MSigDB Hallmarks<sup><xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR58">58</xref></sup> (v5.2) was assessed assuming a hypergeometric distribution using the phyper function in the R package stats<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. Camera gene set analysis<sup><xref ref-type="bibr" rid="CR59">59</xref></sup> and visualization was performed using the R package limma with default parameters and implemented in the CMScaller function CMSgsa. For the latter analysis, gene sets were pre-selected to be likely CMS-informative based on Guinney <italic>et al</italic>. and are listed in Supplementary Table <xref rid="MOESM1" ref-type="media">3</xref>
<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>.</p>
    </sec>
    <sec id="Sec11">
      <title>CMScaller template feature selection</title>
      <p id="Par23">TCGA primary CRC (COADREAD) CMS labels were retrieved from Sage Bionetworks Synapse (syn4978511)<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. TCGA pCRC RNA-sequencing samples<sup><xref ref-type="bibr" rid="CR53">53</xref></sup> were randomly assigned to a training (75%) and test set (25%) using the R function sample. Differential expression analysis in the TCGA test set was used to identify <italic>candidate markers</italic> with higher expression in each subtype compared to the remaining samples (LFC &gt; 1, adjusted-<italic>p</italic> &lt; 0.1). To generate the final template gene set, these candidates markers were enriched for cancer cell-intrinsic expression signals according to the following criteria. RNA-sequencing data for CRC cell lines<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> was used to identify <italic>robust and intrinsic markers</italic>, genes among the top-25% with (i) highest expression in at least three samples and (ii) largest 10–90% inter-percentile range in expression values. limma differential expression analysis comparing pCRC with PDX models<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> was used to further enrich for <italic>intrinsic markers</italic> defined as genes with LFC &lt; 2. The intersection of candidate, robust and intrinsic markers were used as template features for nearest template prediction<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>, which is a correlation-based algorithm developed to provide robust class prediction for high-dimensional, noisy gene expression data, and which has been successfully adopted to various similar classification tasks (<italic>e</italic>.<italic>g</italic>. ref.<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>).</p>
    </sec>
    <sec id="Sec12">
      <title>CMS classification</title>
      <p id="Par24">CMS classifications were performed using either the original classifyCMS.RF function with default settings in the R package CMSclassfier,<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> or the novel CMScaller. With CMScaller, prediction confidence is estimated from gene resampling (<italic>n</italic> = 1000) and samples with false discovery rate adjusted <italic>p</italic>-value &gt; 0.05 were “not assigned” (NA). To assess prediction variance, CMScaller was applied on 8 × 1000 random TCGA train subsets (<italic>n</italic> = {10, 20, …, 80}). To determine whether subtyping is sample-type “cycle consistent”, differential expression analysis of PDXs classified by CMScaller was used to develop new templates for nearest template prediction of the TCGA pCRC test set. Genes used for the PDX classification were not included in this new template.</p>
    </sec>
    <sec id="Sec13">
      <title>Additional statistical analysis</title>
      <p id="Par25">For differential gene expression analysis, hypergeometric gene set tests and nearest template predictions, Benjamini-Hochberg false discovery rate adjustment implemented in the R package stats in the function p.adjust was used to account for multiple-testing<sup><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR60">60</xref></sup>. All reported accuracy values are overall accuracies (the number of classification agreements divided by the number of cases with those not assigned (NA) excluded).</p>
    </sec>
    <sec id="Sec14">
      <title>Data availability</title>
      <p id="Par26">All data analyzed during the current study were retrieved from public sources. In brief, GSE59857, GSE76402, GSE35144, GSE64392 and GSE74843 gene expression datasets were downloaded from Gene Expression Omnibus (GEO). TCGA pCRC gene expression data was downloaded from Broad GDAC Firehose accession doi:10.7908/C11G0KM9. Julien <italic>et al</italic>. PDX and pCRC gene expression dataset E-MTAB-991 was downloaded from ArrayExpress. Additional data was retrieved as described in the relevant Methods sections.</p>
    </sec>
    <sec id="Sec15">
      <title>Code availability</title>
      <p id="Par27">The CMScaller (v0.99.1) R package is available in Supplementary Materials and will be submitted to Bioconductor<sup><xref ref-type="bibr" rid="CR61">61</xref></sup>. Updates will be available on <ext-link ext-link-type="uri" xlink:href="https://github.com/Lothelab/CMScaller">https://github.com/Lothelab/CMScaller</ext-link>. Instructions for installation and example code are given in Supplementary Tables and Figures.</p>
    </sec>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Electronic supplementary material</title>
    <sec id="Sec16">
      <p>
        <supplementary-material content-type="local-data" id="MOESM1">
          <media xlink:href="41598_2017_16747_MOESM1_ESM.pdf">
            <caption>
              <p>Supplementary Tables and Figures</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM2">
          <media xlink:href="41598_2017_16747_MOESM2_ESM.zip">
            <caption>
              <p>CMScaller</p>
            </caption>
          </media>
        </supplementary-material>
      </p>
    </sec>
  </sec>
</body>
<back>
  <fn-group>
    <fn>
      <p>
        <bold>Electronic supplementary material</bold>
      </p>
      <p><bold>Supplementary information</bold> accompanies this paper at 10.1038/s41598-017-16747-x.</p>
    </fn>
    <fn>
      <p><bold>Publisher's note:</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
    </fn>
  </fn-group>
  <ack>
    <title>Acknowledgements</title>
    <p>This work has been supported by the Norwegian Cancer Society, grant numbers 72190-PR-2006–0442, 182759–2017 and 6824048–2016; the foundation Stiftelsen Kristian Gerhard Jebsen; and the Research Council of Norway through FRIPRO Toppforsk project number 250993.</p>
  </ack>
  <notes notes-type="author-contribution">
    <title>Author Contributions</title>
    <p>P.W.E. and A.S. performed the analyses and drafted the manuscript. All authors contributed to study design, data interpretation and the revision and final approval of the manuscript.</p>
  </notes>
  <notes notes-type="COI-statement">
    <sec id="FPar1">
      <title>Competing Interests</title>
      <p id="Par28">The authors declare that they have no competing interests.</p>
    </sec>
  </notes>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ferlay</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012</article-title>
        <source>Int J Cancer</source>
        <year>2015</year>
        <volume>136</volume>
        <fpage>E359</fpage>
        <lpage>E386</lpage>
        <pub-id pub-id-type="doi">10.1002/ijc.29210</pub-id>
        <?supplied-pmid 25220842?>
        <pub-id pub-id-type="pmid">25220842</pub-id>
      </element-citation>
    </ref>
    <ref id="CR2">
      <label>2.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Budinska</surname>
            <given-names>E</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer</article-title>
        <source>J Pathol</source>
        <year>2013</year>
        <volume>231</volume>
        <fpage>63</fpage>
        <lpage>76</lpage>
        <pub-id pub-id-type="doi">10.1002/path.4212</pub-id>
        <?supplied-pmid 23836465?>
        <pub-id pub-id-type="pmid">23836465</pub-id>
      </element-citation>
    </ref>
    <ref id="CR3">
      <label>3.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Melo</surname>
            <given-names>FDSE</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions</article-title>
        <source>Nat Med</source>
        <year>2013</year>
        <volume>19</volume>
        <fpage>614</fpage>
        <lpage>618</lpage>
        <pub-id pub-id-type="doi">10.1038/nm.3174</pub-id>
        <pub-id pub-id-type="pmid">23584090</pub-id>
      </element-citation>
    </ref>
    <ref id="CR4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Marisa</surname>
            <given-names>L</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value</article-title>
        <source>PLoS Med</source>
        <year>2013</year>
        <volume>10</volume>
        <fpage>e1001453</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pmed.1001453</pub-id>
        <?supplied-pmid 23700391?>
        <pub-id pub-id-type="pmid">23700391</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sadanandam</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A colorectal cancer classification system that associates cellular phenotype and responses to therapy</article-title>
        <source>Nat Med</source>
        <year>2013</year>
        <volume>19</volume>
        <fpage>619</fpage>
        <lpage>625</lpage>
        <pub-id pub-id-type="doi">10.1038/nm.3175</pub-id>
        <?supplied-pmid 23584089?>
        <pub-id pub-id-type="pmid">23584089</pub-id>
      </element-citation>
    </ref>
    <ref id="CR6">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Schlicker</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines</article-title>
        <source>BMC Med Genomics</source>
        <year>2012</year>
        <volume>5</volume>
        <fpage>66</fpage>
        <pub-id pub-id-type="doi">10.1186/1755-8794-5-66</pub-id>
        <?supplied-pmid 23272949?>
        <pub-id pub-id-type="pmid">23272949</pub-id>
      </element-citation>
    </ref>
    <ref id="CR7">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Isella</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Stromal contribution to the colorectal cancer transcriptome</article-title>
        <source>Nat Genet</source>
        <year>2015</year>
        <volume>47</volume>
        <fpage>312</fpage>
        <lpage>319</lpage>
        <pub-id pub-id-type="doi">10.1038/ng.3224</pub-id>
        <?supplied-pmid 25706627?>
        <pub-id pub-id-type="pmid">25706627</pub-id>
      </element-citation>
    </ref>
    <ref id="CR8">
      <label>8.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Song</surname>
            <given-names>N</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial</article-title>
        <source>JAMA Oncol</source>
        <year>2016</year>
        <volume>2</volume>
        <fpage>1162</fpage>
        <lpage>1169</lpage>
        <pub-id pub-id-type="doi">10.1001/jamaoncol.2016.2314</pub-id>
        <?supplied-pmid 27270348?>
        <pub-id pub-id-type="pmid">27270348</pub-id>
      </element-citation>
    </ref>
    <ref id="CR9">
      <label>9.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Trinh</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry</article-title>
        <source>Clin Cancer Res</source>
        <year>2017</year>
        <volume>23</volume>
        <fpage>387</fpage>
        <lpage>398</lpage>
        <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-0680</pub-id>
        <?supplied-pmid 27459899?>
        <pub-id pub-id-type="pmid">27459899</pub-id>
      </element-citation>
    </ref>
    <ref id="CR10">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Guinney</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The consensus molecular subtypes of colorectal cancer</article-title>
        <source>Nat Med</source>
        <year>2015</year>
        <volume>21</volume>
        <fpage>1350</fpage>
        <lpage>1356</lpage>
        <pub-id pub-id-type="doi">10.1038/nm.3967</pub-id>
        <?supplied-pmid 26457759?>
        <pub-id pub-id-type="pmid">26457759</pub-id>
      </element-citation>
    </ref>
    <ref id="CR11">
      <label>11.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dienstmann</surname>
            <given-names>R</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer</article-title>
        <source>Nat Rev Cancer</source>
        <year>2017</year>
        <volume>17</volume>
        <fpage>79</fpage>
        <lpage>92</lpage>
        <pub-id pub-id-type="doi">10.1038/nrc.2016.126</pub-id>
        <?supplied-pmid 28050011?>
        <pub-id pub-id-type="pmid">28050011</pub-id>
      </element-citation>
    </ref>
    <ref id="CR12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Barretina</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity</article-title>
        <source>Nature</source>
        <year>2012</year>
        <volume>483</volume>
        <fpage>603</fpage>
        <lpage>307</lpage>
        <pub-id pub-id-type="doi">10.1038/nature11003</pub-id>
        <?supplied-pmid 22460905?>
        <pub-id pub-id-type="pmid">22460905</pub-id>
      </element-citation>
    </ref>
    <ref id="CR13">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Berg</surname>
            <given-names>KCG</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies</article-title>
        <source>Mol Cancer</source>
        <year>2017</year>
        <volume>16</volume>
        <fpage>116</fpage>
        <pub-id pub-id-type="doi">10.1186/s12943-017-0691-y</pub-id>
        <?supplied-pmid 28683746?>
        <pub-id pub-id-type="pmid">28683746</pub-id>
      </element-citation>
    </ref>
    <ref id="CR14">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Julien</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer</article-title>
        <source>Clin Cancer Res</source>
        <year>2012</year>
        <volume>18</volume>
        <fpage>5314</fpage>
        <lpage>5328</lpage>
        <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-0372</pub-id>
        <?supplied-pmid 22825584?>
        <pub-id pub-id-type="pmid">22825584</pub-id>
      </element-citation>
    </ref>
    <ref id="CR15">
      <label>15.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fujii</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche Factor Requirements during Tumorigenesis</article-title>
        <source>Cell Stem Cell</source>
        <year>2016</year>
        <volume>18</volume>
        <fpage>827</fpage>
        <lpage>838</lpage>
        <pub-id pub-id-type="doi">10.1016/j.stem.2016.04.003</pub-id>
        <?supplied-pmid 27212702?>
        <pub-id pub-id-type="pmid">27212702</pub-id>
      </element-citation>
    </ref>
    <ref id="CR16">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wetering</surname>
            <given-names>Mvande</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Prospective derivation of a living organoid biobank of colorectal cancer patients</article-title>
        <source>Cell</source>
        <year>2015</year>
        <volume>161</volume>
        <fpage>933</fpage>
        <lpage>945</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2015.03.053</pub-id>
        <?supplied-pmid 25957691?>
        <pub-id pub-id-type="pmid">25957691</pub-id>
      </element-citation>
    </ref>
    <ref id="CR17">
      <label>17.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pauli</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Personalized <italic>In Vitro</italic> and <italic>In Vivo</italic> Cancer Models to Guide Precision Medicine</article-title>
        <source>Cancer Discov</source>
        <year>2017</year>
        <volume>7</volume>
        <fpage>462</fpage>
        <lpage>477</lpage>
        <pub-id pub-id-type="doi">10.1158/2159-8290.CD-16-1154</pub-id>
        <?supplied-pmid 28331002?>
        <pub-id pub-id-type="pmid">28331002</pub-id>
      </element-citation>
    </ref>
    <ref id="CR18">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Schütte</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors</article-title>
        <source>Nat Commun</source>
        <year>2017</year>
        <volume>8</volume>
        <fpage>14262</fpage>
        <pub-id pub-id-type="doi">10.1038/ncomms14262</pub-id>
        <?supplied-pmid 28186126?>
        <pub-id pub-id-type="pmid">28186126</pub-id>
      </element-citation>
    </ref>
    <ref id="CR19">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dunne</surname>
            <given-names>PD</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification</article-title>
        <source>Nat Commun</source>
        <year>2017</year>
        <volume>8</volume>
        <fpage>ncomms15657</fpage>
        <pub-id pub-id-type="doi">10.1038/ncomms15657</pub-id>
      </element-citation>
    </ref>
    <ref id="CR20">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Isella</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer</article-title>
        <source>Nat Commun</source>
        <year>2017</year>
        <volume>8</volume>
        <fpage>ncomms15107</fpage>
        <pub-id pub-id-type="doi">10.1038/ncomms15107</pub-id>
      </element-citation>
    </ref>
    <ref id="CR21">
      <label>21.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Calon</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Stromal gene expression defines poor-prognosis subtypes in colorectal cancer</article-title>
        <source>Nat Genet</source>
        <year>2015</year>
        <volume>47</volume>
        <fpage>320</fpage>
        <lpage>329</lpage>
        <pub-id pub-id-type="doi">10.1038/ng.3225</pub-id>
        <?supplied-pmid 25706628?>
        <pub-id pub-id-type="pmid">25706628</pub-id>
      </element-citation>
    </ref>
    <ref id="CR22">
      <label>22.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Becht</surname>
            <given-names>E</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy</article-title>
        <source>Clin Cancer Res</source>
        <year>2016</year>
        <volume>22</volume>
        <fpage>4057</fpage>
        <lpage>4066</lpage>
        <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-2879</pub-id>
        <?supplied-pmid 26994146?>
        <pub-id pub-id-type="pmid">26994146</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fessler</surname>
            <given-names>E</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A multidimensional network approach reveals microRNAs as determinants of the mesenchymal colorectal cancer subtype</article-title>
        <source>Oncogene</source>
        <year>2016</year>
        <volume>35</volume>
        <fpage>6026</fpage>
        <lpage>6037</lpage>
        <pub-id pub-id-type="doi">10.1038/onc.2016.134</pub-id>
        <?supplied-pmid 27157610?>
        <pub-id pub-id-type="pmid">27157610</pub-id>
      </element-citation>
    </ref>
    <ref id="CR24">
      <label>24.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sztupinszki</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Győrffy</surname>
            <given-names>B</given-names>
          </name>
        </person-group>
        <article-title>Colon cancer subtypes: Concordance, effect on survival and selection of the most representative preclinical models</article-title>
        <source>Sci Rep</source>
        <year>2016</year>
        <volume>6</volume>
        <fpage>37169</fpage>
        <pub-id pub-id-type="doi">10.1038/srep37169</pub-id>
        <?supplied-pmid 27849044?>
        <pub-id pub-id-type="pmid">27849044</pub-id>
      </element-citation>
    </ref>
    <ref id="CR25">
      <label>25.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Katsiampoura</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Modeling of Patient-Derived Xenografts in Colorectal Cancer</article-title>
        <source>Mol Cancer Ther</source>
        <year>2017</year>
        <volume>16</volume>
        <fpage>1435</fpage>
        <lpage>1442</lpage>
        <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-16-0721</pub-id>
        <?supplied-pmid 28468778?>
        <pub-id pub-id-type="pmid">28468778</pub-id>
      </element-citation>
    </ref>
    <ref id="CR26">
      <label>26.</label>
      <mixed-citation publication-type="other">R Core Team. <italic>R: A Language and Environment for Statistical Computing</italic>. (R Foundation for Statistical Computing, 2017).</mixed-citation>
    </ref>
    <ref id="CR27">
      <label>27.</label>
      <mixed-citation publication-type="other">Medico, E. <italic>et al</italic>. The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. <italic>Nat Commun</italic><bold>6</bold>, (2015).</mixed-citation>
    </ref>
    <ref id="CR28">
      <label>28.</label>
      <mixed-citation publication-type="other">Uronis, J. M. <italic>et al</italic>. Histological and Molecular Evaluation of Patient-Derived Colorectal Cancer Explants. <italic>PLoS One</italic><bold>7</bold>, (2012).</mixed-citation>
    </ref>
    <ref id="CR29">
      <label>29.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gao</surname>
            <given-names>H</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response</article-title>
        <source>Nat Med</source>
        <year>2015</year>
        <volume>21</volume>
        <fpage>1318</fpage>
        <lpage>1325</lpage>
        <pub-id pub-id-type="doi">10.1038/nm.3954</pub-id>
        <?supplied-pmid 26479923?>
        <pub-id pub-id-type="pmid">26479923</pub-id>
      </element-citation>
    </ref>
    <ref id="CR30">
      <label>30.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Croft</surname>
            <given-names>D</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The Reactome pathway knowledgebase</article-title>
        <source>Nucl Acids Res</source>
        <year>2014</year>
        <volume>42</volume>
        <fpage>D472</fpage>
        <lpage>D477</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkt1102</pub-id>
        <?supplied-pmid 24243840?>
        <pub-id pub-id-type="pmid">24243840</pub-id>
      </element-citation>
    </ref>
    <ref id="CR31">
      <label>31.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Liberzon</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The Molecular Signatures Database Hallmark Gene Set Collection</article-title>
        <source>Cell Systems</source>
        <year>2015</year>
        <volume>1</volume>
        <fpage>417</fpage>
        <lpage>425</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cels.2015.12.004</pub-id>
        <?supplied-pmid 26771021?>
        <pub-id pub-id-type="pmid">26771021</pub-id>
      </element-citation>
    </ref>
    <ref id="CR32">
      <label>32.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Klijn</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A comprehensive transcriptional portrait of human cancer cell lines</article-title>
        <source>Nat Biotech</source>
        <year>2015</year>
        <volume>33</volume>
        <fpage>306</fpage>
        <lpage>312</lpage>
        <pub-id pub-id-type="doi">10.1038/nbt.3080</pub-id>
      </element-citation>
    </ref>
    <ref id="CR33">
      <label>33.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hoshida</surname>
            <given-names>Y</given-names>
          </name>
        </person-group>
        <article-title>Nearest Template Prediction: A Single-Sample-Based Flexible Class Prediction with Confidence Assessment</article-title>
        <source>PLoS One</source>
        <year>2010</year>
        <volume>5</volume>
        <fpage>e15543</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pone.0015543</pub-id>
        <?supplied-pmid 21124904?>
        <pub-id pub-id-type="pmid">21124904</pub-id>
      </element-citation>
    </ref>
    <ref id="CR34">
      <label>34.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity</article-title>
        <source>Gastroenterology</source>
        <year>2017</year>
        <volume>153</volume>
        <fpage>1082</fpage>
        <lpage>1095</lpage>
        <pub-id pub-id-type="doi">10.1053/j.gastro.2017.06.008</pub-id>
        <?supplied-pmid 28625833?>
        <pub-id pub-id-type="pmid">28625833</pub-id>
      </element-citation>
    </ref>
    <ref id="CR35">
      <label>35.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ashraf</surname>
            <given-names>SQ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel</article-title>
        <source>PNAS</source>
        <year>2012</year>
        <volume>109</volume>
        <fpage>21046</fpage>
        <lpage>21051</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.1218750110</pub-id>
        <?supplied-pmid 23213241?>
        <pub-id pub-id-type="pmid">23213241</pub-id>
      </element-citation>
    </ref>
    <ref id="CR36">
      <label>36.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sargent</surname>
            <given-names>DJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in ColonCancer</article-title>
        <source>JCO</source>
        <year>2010</year>
        <volume>28</volume>
        <fpage>3219</fpage>
        <lpage>3226</lpage>
        <pub-id pub-id-type="doi">10.1200/JCO.2009.27.1825</pub-id>
      </element-citation>
    </ref>
    <ref id="CR37">
      <label>37.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bracht</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Nicholls</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Bodmer</surname>
            <given-names>WF</given-names>
          </name>
        </person-group>
        <article-title>5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency</article-title>
        <source>Br J Cancer</source>
        <year>2010</year>
        <volume>103</volume>
        <fpage>340</fpage>
        <lpage>346</lpage>
        <pub-id pub-id-type="doi">10.1038/sj.bjc.6605780</pub-id>
        <?supplied-pmid 20606684?>
        <pub-id pub-id-type="pmid">20606684</pub-id>
      </element-citation>
    </ref>
    <ref id="CR38">
      <label>38.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Roepman</surname>
            <given-names>P</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition</article-title>
        <source>Int J Cancer</source>
        <year>2014</year>
        <volume>134</volume>
        <fpage>552</fpage>
        <lpage>562</lpage>
        <pub-id pub-id-type="doi">10.1002/ijc.28387</pub-id>
        <?supplied-pmid 23852808?>
        <pub-id pub-id-type="pmid">23852808</pub-id>
      </element-citation>
    </ref>
    <ref id="CR39">
      <label>39.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tauriello</surname>
            <given-names>DVF</given-names>
          </name>
          <name>
            <surname>Calon</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Lonardo</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Batlle</surname>
            <given-names>E</given-names>
          </name>
        </person-group>
        <article-title>Determinants of metastatic competency in colorectal cancer</article-title>
        <source>Mol Oncol</source>
        <year>2017</year>
        <volume>11</volume>
        <fpage>97</fpage>
        <lpage>119</lpage>
        <pub-id pub-id-type="doi">10.1002/1878-0261.12018</pub-id>
        <?supplied-pmid 28085225?>
        <pub-id pub-id-type="pmid">28085225</pub-id>
      </element-citation>
    </ref>
    <ref id="CR40">
      <label>40.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bramsen</surname>
            <given-names>JB</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Molecular-Subtype-Specific Biomarkers Improve Prediction of Prognosis in Colorectal Cancer</article-title>
        <source>Cell Reports</source>
        <year>2017</year>
        <volume>19</volume>
        <fpage>1268</fpage>
        <lpage>1280</lpage>
        <pub-id pub-id-type="doi">10.1016/j.celrep.2017.04.045</pub-id>
        <?supplied-pmid 28494874?>
        <pub-id pub-id-type="pmid">28494874</pub-id>
      </element-citation>
    </ref>
    <ref id="CR41">
      <label>41.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Heimberg</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Bhatnagar</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>El-Samad</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Thomson</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Low Dimensionality in Gene Expression Data Enables the Accurate Extraction of Transcriptional Programs from Shallow Sequencing</article-title>
        <source>Cell Systems</source>
        <year>2016</year>
        <volume>2</volume>
        <fpage>239</fpage>
        <lpage>250</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cels.2016.04.001</pub-id>
        <?supplied-pmid 27135536?>
        <pub-id pub-id-type="pmid">27135536</pub-id>
      </element-citation>
    </ref>
    <ref id="CR42">
      <label>42.</label>
      <mixed-citation publication-type="other">Zhao, X., Rødland, E. A., Tibshirani, R. &amp; Plevritis, S. Molecular subtyping for clinically defined breast cancer subgroups. <italic>Breast Cancer Res</italic><bold>17</bold>, (2015).</mixed-citation>
    </ref>
    <ref id="CR43">
      <label>43.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dunne</surname>
            <given-names>PD</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer</article-title>
        <source>Clin Cancer Res</source>
        <year>2016</year>
        <volume>22</volume>
        <fpage>4095</fpage>
        <lpage>4104</lpage>
        <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-0032</pub-id>
        <?supplied-pmid 27151745?>
        <pub-id pub-id-type="pmid">27151745</pub-id>
      </element-citation>
    </ref>
    <ref id="CR44">
      <label>44.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Morris</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>Kopetz</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Tumor Microenvironment in Gene Signatures: Critical Biology or Confounding Noise?</article-title>
        <source>Clin Cancer Res</source>
        <year>2016</year>
        <volume>22</volume>
        <fpage>3989</fpage>
        <lpage>3991</lpage>
        <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-1044</pub-id>
        <?supplied-pmid 27334836?>
        <pub-id pub-id-type="pmid">27334836</pub-id>
      </element-citation>
    </ref>
    <ref id="CR45">
      <label>45.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sottoriva</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A Big Bang model of human colorectal tumor growth</article-title>
        <source>Nat Genet</source>
        <year>2015</year>
        <volume>47</volume>
        <fpage>209</fpage>
        <lpage>216</lpage>
        <pub-id pub-id-type="doi">10.1038/ng.3214</pub-id>
        <?supplied-pmid 25665006?>
        <pub-id pub-id-type="pmid">25665006</pub-id>
      </element-citation>
    </ref>
    <ref id="CR46">
      <label>46.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>H</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors</article-title>
        <source>Nat Genet</source>
        <year>2017</year>
        <volume>49</volume>
        <fpage>708</fpage>
        <lpage>718</lpage>
        <pub-id pub-id-type="doi">10.1038/ng.3818</pub-id>
        <?supplied-pmid 28319088?>
        <pub-id pub-id-type="pmid">28319088</pub-id>
      </element-citation>
    </ref>
    <ref id="CR47">
      <label>47.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hansen</surname>
            <given-names>KD</given-names>
          </name>
          <name>
            <surname>Irizarry</surname>
            <given-names>RA</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>Z</given-names>
          </name>
        </person-group>
        <article-title>Removing technical variability in RNA-seq data using conditional quantile normalization</article-title>
        <source>Biostat</source>
        <year>2012</year>
        <volume>13</volume>
        <fpage>204</fpage>
        <lpage>216</lpage>
        <pub-id pub-id-type="doi">10.1093/biostatistics/kxr054</pub-id>
      </element-citation>
    </ref>
    <ref id="CR48">
      <label>48.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Love</surname>
            <given-names>MI</given-names>
          </name>
          <name>
            <surname>Huber</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Anders</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq. 2</article-title>
        <source>Genome Biol</source>
        <year>2014</year>
        <volume>15</volume>
        <fpage>550</fpage>
        <pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id>
        <?supplied-pmid 25516281?>
        <pub-id pub-id-type="pmid">25516281</pub-id>
      </element-citation>
    </ref>
    <ref id="CR49">
      <label>49.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Barrett</surname>
            <given-names>T</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>NCBI GEO: Archive for functional genomics data sets—update</article-title>
        <source>Nucl Acids Res</source>
        <year>2013</year>
        <volume>41</volume>
        <fpage>D991</fpage>
        <lpage>D995</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gks1193</pub-id>
        <?supplied-pmid 23193258?>
        <pub-id pub-id-type="pmid">23193258</pub-id>
      </element-citation>
    </ref>
    <ref id="CR50">
      <label>50.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kolesnikov</surname>
            <given-names>N</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>ArrayExpress update—simplifying data submissions</article-title>
        <source>Nucl Acids Res</source>
        <year>2015</year>
        <volume>43</volume>
        <fpage>D1113</fpage>
        <lpage>D1116</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gku1057</pub-id>
        <?supplied-pmid 25361974?>
        <pub-id pub-id-type="pmid">25361974</pub-id>
      </element-citation>
    </ref>
    <ref id="CR51">
      <label>51.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gautier</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Cope</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Bolstad</surname>
            <given-names>BM</given-names>
          </name>
          <name>
            <surname>Irizarry</surname>
            <given-names>RA</given-names>
          </name>
        </person-group>
        <article-title>Affy—analysis of Affymetrix GeneChip data at the probe level</article-title>
        <source>Bioinformatics</source>
        <year>2004</year>
        <volume>20</volume>
        <fpage>307</fpage>
        <lpage>315</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btg405</pub-id>
        <?supplied-pmid 14960456?>
        <pub-id pub-id-type="pmid">14960456</pub-id>
      </element-citation>
    </ref>
    <ref id="CR52">
      <label>52.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sandberg</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Larsson</surname>
            <given-names>O</given-names>
          </name>
        </person-group>
        <article-title>Improved precision and accuracy for microarrays using updated probe set definitions</article-title>
        <source>BMC Bioinformatics</source>
        <year>2007</year>
        <volume>8</volume>
        <fpage>1</fpage>
        <pub-id pub-id-type="doi">10.1186/1471-2105-8-48</pub-id>
        <pub-id pub-id-type="pmid">17199892</pub-id>
      </element-citation>
    </ref>
    <ref id="CR53">
      <label>53.</label>
      <mixed-citation publication-type="other">TCGA. Comprehensive molecular characterization of human colon and rectal cancer. <italic>Nature</italic><bold>487</bold>, 330–337 (2012).</mixed-citation>
    </ref>
    <ref id="CR54">
      <label>54.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hänzelmann</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Castelo</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Guinney</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>GSVA: Gene set variation analysis for microarray and RNA-Seq data</article-title>
        <source>BMC Bioinformatics</source>
        <year>2013</year>
        <volume>14</volume>
        <fpage>7</fpage>
        <pub-id pub-id-type="doi">10.1186/1471-2105-14-7</pub-id>
        <?supplied-pmid 23323831?>
        <pub-id pub-id-type="pmid">23323831</pub-id>
      </element-citation>
    </ref>
    <ref id="CR55">
      <label>55.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ritchie</surname>
            <given-names>ME</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title>
        <source>Nucl Acids Res</source>
        <year>2015</year>
        <volume>43</volume>
        <fpage>e47</fpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id>
        <?supplied-pmid 25605792?>
        <pub-id pub-id-type="pmid">25605792</pub-id>
      </element-citation>
    </ref>
    <ref id="CR56">
      <label>56.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Law</surname>
            <given-names>CW</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Shi</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Smyth</surname>
            <given-names>GK</given-names>
          </name>
        </person-group>
        <article-title>Voom: Precision weights unlock linear model analysis tools for RNA-seq read counts</article-title>
        <source>Genome Biology</source>
        <year>2014</year>
        <volume>15</volume>
        <fpage>R29</fpage>
        <pub-id pub-id-type="doi">10.1186/gb-2014-15-2-r29</pub-id>
        <?supplied-pmid 24485249?>
        <pub-id pub-id-type="pmid">24485249</pub-id>
      </element-citation>
    </ref>
    <ref id="CR57">
      <label>57.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Leek</surname>
            <given-names>JT</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Tackling the widespread and critical impact of batch effects in high-throughput data</article-title>
        <source>Nat Rev Genet</source>
        <year>2010</year>
        <volume>11</volume>
        <fpage>733</fpage>
        <lpage>739</lpage>
        <pub-id pub-id-type="doi">10.1038/nrg2825</pub-id>
        <?supplied-pmid 20838408?>
        <pub-id pub-id-type="pmid">20838408</pub-id>
      </element-citation>
    </ref>
    <ref id="CR58">
      <label>58.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Subramanian</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles</article-title>
        <source>PNAS</source>
        <year>2005</year>
        <volume>102</volume>
        <fpage>15545</fpage>
        <lpage>15550</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id>
        <?supplied-pmid 16199517?>
        <pub-id pub-id-type="pmid">16199517</pub-id>
      </element-citation>
    </ref>
    <ref id="CR59">
      <label>59.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Smyth</surname>
            <given-names>GK</given-names>
          </name>
        </person-group>
        <article-title>Camera: A competitive gene set test accounting for inter-gene correlation</article-title>
        <source>Nucl Acids Res</source>
        <year>2012</year>
        <volume>40</volume>
        <fpage>e133</fpage>
        <pub-id pub-id-type="doi">10.1093/nar/gks461</pub-id>
        <?supplied-pmid 22638577?>
        <pub-id pub-id-type="pmid">22638577</pub-id>
      </element-citation>
    </ref>
    <ref id="CR60">
      <label>60.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Benjamini</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Hochberg</surname>
            <given-names>Y</given-names>
          </name>
        </person-group>
        <article-title>Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing</article-title>
        <source>J Royal Stat Soc</source>
        <year>1995</year>
        <volume>57</volume>
        <fpage>289</fpage>
        <lpage>300</lpage>
      </element-citation>
    </ref>
    <ref id="CR61">
      <label>61.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Huber</surname>
            <given-names>W</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Orchestrating high-throughput genomic analysis with Bioconductor</article-title>
        <source>Nat Meth</source>
        <year>2015</year>
        <volume>12</volume>
        <fpage>115</fpage>
        <lpage>121</lpage>
        <pub-id pub-id-type="doi">10.1038/nmeth.3252</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
